Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q3
Sell
-281,027
Closed -$2.76M 1685
2025
Q2
$2.76M Buy
281,027
+181,844
+183% +$1.51M 0.03% 769
2025
Q1
$721K Buy
+99,183
New +$867K 0.01% 1188
2024
Q4
Sell
-54,389
Closed -$402K 1636
2024
Q3
$402K Sell
54,389
-109,227
-67% -$918K 0.01% 1287
2024
Q2
$1.31M Buy
163,616
+109,346
+201% +$976K 0.02% 907
2024
Q1
$632K Buy
+54,270
New +$601K 0.01% 1076
2023
Q1
Sell
-62,034
Closed -$790K 1525
2022
Q4
$790K Buy
+62,034
New +$558K 0.02% 737
2022
Q2
Sell
-26,433
Closed -$100K 1607
2022
Q1
$100K Buy
26,433
+13,025
+97% +$83.9K ﹤0.01% 1275
2021
Q4
$175K Buy
+13,408
New +$212K 0.01% 1176

Other funds holding ETNB

Trexquant Investment's ETNB Position: Q3 2025 in Review

Trexquant Investment sold out of 89bio (ETNB) in Q3 2025, closing a stake of 281,027 shares — an estimated $2.76M sold.

Trexquant Investment first reported a position in ETNB in Q4 2021 and held it in 8 quarters. The position peaked at $2.76M in Q2 2025. 198 funds tracked by Wall St. Rank hold ETNB as of Q3 2025.

  • Trexquant Investment reported no remaining 89bio position as of Q3 2025 after selling out during the quarter.
  • Trexquant Investment sold 281,027 89bio shares in Q3 2025, an estimated $2.76M.
  • Trexquant Investment first reported a position in 89bio in Q4 2021 and held it in 8 quarters.
  • Trexquant Investment's 89bio position peaked at $2.76M in Q2 2025.
  • 198 funds tracked by Wall St. Rank held 89bio as of Q3 2025.

Based on Trexquant Investment's 13F filing for Q3 2025, filed 14 Nov 2025.